Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

metabolic · Mechanism Report

Can impaired kidney function raise circulating TMAO independently of microbial production?

Impaired renal function can substantially increase circulating TMAO by reducing renal clearance.

PlausibleOctober 16, 20265 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

TMAO is substantially cleared by the kidneys, so impaired renal function can increase circulating TMAO independently of microbial production.

laying out figure…
1 of 2 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says TMAO is mainly eliminated by the kidneys, so reduced kidney function can leave more of it in circulation. The mechanism framing shows TMAO as the end result of microbial and hepatic production, but with kidney clearance as a major determinant of its measured level. In that context, elevated TMAO reflects both production and elimination rather than gut activity alone.

Verified conclusion

TMAO reflects both upstream production and downstream elimination. In a 71-year-old man, an elevated result should therefore be interpreted in the context of kidney function, not as a direct readout of gut-microbial activity alone.

Renal clearance and clinical evidence

  • Kidney-mediated elimination is a major route for TMAO, which is largely excreted unchanged in urine. In human plasma–urine studies, TMAO fractional excretion averaged 105% ± 32% of measured GFR, closely consistent with predominantly glomerular-filtration–based clearance.
  • Circulating TMAO rises substantially as renal function declines: compared with controls, concentrations were approximately 3-fold higher in CKD stage 3, 7-fold higher in stages 4–5, and 28-fold higher in dialysis patients.
  • The plasma TMAO–GFR relationship was significant in measured-clearance data (r²=0.388; p<0.001). Hemodiafiltration reduced TMAO by 84.9% ± 6.5% over four hours, directly demonstrating removal of the retained circulating pool.

Mechanistic interpretation

  • Gut microbes convert dietary choline, phosphatidylcholine, and L-carnitine to trimethylamine (TMA); the liver converts TMA to TMAO.
  • Reduced GFR can increase circulating TMAO through retention of this molecule after it is produced. Thus, higher TMAO does not require increased microbial production, although microbial and dietary precursor supply still determines how much TMAO enters the circulation.
  • In multi-cohort modeling, diet and microbiota taxonomic measures explained relatively small proportions of model-explainable TMAO variation (4% and 3.4%, respectively), while eGFR was strongly interlinked with TMAO.

Clinical implications

  • TMAO is also associated prospectively with incident CKD and faster eGFR decline, but this predictive association does not establish that TMAO itself causes kidney injury.
  • Bottom line: The claim is well supported: impaired renal function can materially elevate circulating TMAO through reduced renal clearance, independently of any increase in microbial production.

References

  1. Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease — pmc.ncbi.nlm.nih.gov ↗
  2. Contribution of multidrug and toxin extrusion protein 1 (MATE1) to renal secretion of trimethylamine-N-oxide (TMAO) — pmc.ncbi.nlm.nih.gov ↗
  3. Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N -oxide — nature.com ↗
  4. Diet and Chronic Kidney Disease - PMC - NIH — pmc.ncbi.nlm.nih.gov ↗
  5. The Gut Microbial Metabolite Trimethylamine N-oxide, Incident ... — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible12 sourcesDoes a C-peptide of 8.87 with glucose 197 suggest insulin resistance?→Plausible8 sourcesDoes skeletal muscle account for major glucose disposal and increase uptake during contraction?→